Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 9/20 | 0.60 |
| ▸ | GFRA3 | O60609 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GFRA2 | O00451 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745432 | 0.87 | FFAR1 (0.57) | FFAR1SRD5A2EPHX2 | |
| SCHEMBL1633343 | 0.87 | FFAR1 (0.57) | FFAR1SRD5A2EPHX2 | |
| SCHEMBL1633344 | 0.87 | FFAR1 (0.57) | FFAR1SRD5A2EPHX2 | |
| SCHEMBL1745194 | 0.86 | FFAR1 (0.54) | FFAR1GFRA3ALDH1A1GFRA2IDO1 | |
| SCHEMBL1746652 | 0.86 | GFRA3 (0.63) | FFAR1GFRA3RETGFRA2IDO1 | |
| SCHEMBL1746407 | 0.84 | FFAR1 (0.60) | FFAR1ALDH1A1IDO1TSHR | |
| SCHEMBL12017975 | 0.81 | IDO1 (0.61) | FFAR1GFRA3GFRA2IDO1 | |
| SCHEMBL1744543 | 0.80 | FFAR1 (0.59) | FFAR1ALDH1A1IDO1RXRARXRB | |
| SCHEMBL1745508 | 0.80 | FFAR1 (0.56) | FFAR1ALDH1A1SRD5A2RXRARXRB | |
| SCHEMBL1744694 | 0.79 | FFAR1 (0.72) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | FFAR1 33/4885GFRA3 250/4885RET 516/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | FFAR1 33/4885GFRA3 412/4885RET 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.